人类胰岛素市场规模、份额和成长分析（按产品、类型、品牌、给药装置、糖尿病和地区）- 2025-2032 年产业预测

2023 年人类胰岛素市场规模价值 193.7 亿美元，预计将从 2024 年的 202.8 亿美元成长到 2032 年的 292.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.7%。

人类胰岛素市场对于糖尿病管理至关重要，为数百万受第 1 型和第 2 型糖尿病影响的患者提供基本治疗。国际糖尿病联盟预测，到2045年，患有糖尿病的成年人数量将从2019年的4.63亿增加到7亿，预计将大幅增加对胰岛素的需求并推动市场成长。製造技术的发展，特别是重组DNA技术，使得胰岛素更安全、更有效，也提高了病人的接受度。医疗保健组织、政府和非政府组织之间的合作旨在提高人们的认识并改善获得胰岛素的机会，特别是在低收入地区。然而，高昂的製造成本和监管挑战阻碍了其普及。向模拟胰岛素的转变、笔和帮浦等创新输送设备的日益普及，再加上人工智慧的整合，是提高治疗依从性和扩大市场的一些显着趋势。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

人类胰岛素市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• HI 药物
• HI 输送装置

人类胰岛素市场规模（按类型和复合年增长率） (2025-2032)

• 市场概况
• 胰岛素类似物和生物相似药
  • 立即见效
  • 长效
  • 预混合料
• HI 生物製剂
  • 短效
  • 中效
  • 预混合料

人类胰岛素市场规模（按品牌和复合年增长率） (2025-2032)

• 市场概况
• HI 类似物和生物相似药
  • 来得时
  • 诺和Rapid/NovoLog
  • Humalog
  • 其他品牌
• HI 生物製剂
  • Actrapid、Insulatard、Mixtard
  • 优泌林
  • 旅馆老闆

人类胰岛素市场规模（按输送装置和复合年增长率） (2025-2032)

• 市场概况
• 笔
  • 可重复使用的
  • 一次性的
• 笔针
  • 标准
  • 安全
• 注射器

人类胰岛素市场规模（按糖尿病类型和复合年增长率） (2025-2032)

• 市场概况
• 1 型糖尿病
• 2 型糖尿病

人类胰岛素市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Novo Nordisk（Denmark）
• Eli Lilly and Company（United States）
• Sanofi（France）
• Biocon Limited（India）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• AstraZeneca（United Kingdom）
• Boehringer Ingelheim（Germany）
• Tonghua Dongbao Pharmaceutical Co., Ltd.（China）
• Wockhardt（India）
• Julphar（United Arab Emirates）
• Oramed Pharmaceuticals Inc.（United States）
• Adocia（France）
• MannKind Corporation（United States）
• Gan & Lee Pharmaceuticals（China）
• Ypsomed（Switzerland）
• Medtronic（Ireland）
• Dexcom（United States）
• Insulet Corporation（United States）
• Senseonics Holdings, Inc.（United States）

结论和建议

Human Insulin Market size was valued at USD 19.37 billion in 2023 and is poised to grow from USD 20.28 billion in 2024 to USD 29.29 billion by 2032, growing at a CAGR of 4.7% during the forecast period (2025-2032).

The human insulin market is crucial for diabetes management, providing essential treatment to millions impacted by type 1 and type 2 diabetes. With the International Diabetes Federation projecting an increase from 463 million diabetic adults in 2019 to 700 million by 2045, the demand for insulin is expected to rise significantly, driving market growth. Advances in production techniques, particularly recombinant DNA technology, have led to the development of safer and more effective insulin, enhancing patient acceptance. Collaborations among healthcare organizations, governments, and NGOs aim to raise awareness and improve insulin accessibility, especially in low-income regions. However, high production costs and regulatory challenges hinder affordability. The shift towards analog insulins and the rising popularity of innovative delivery devices like pens and pumps, supplemented by AI integration, are notable trends in enhancing treatment adherence and market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Human Insulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Human Insulin Market Segments Analysis

Global Human Insulin Market is segmented by Product, Type, Brand, Delivery Devices, Diabetes and region. Based on Product, the market is segmented into HI Drugs and HI Delivery Devices. Based on Type, the market is segmented into Insulin Analogs and Biosimilars and HI Biologics. Based on Brand, the market is segmented into HI Analogs and Biosimilars and HI Biologics. Based on Delivery Devices, the market is segmented into Pens, Pen Needles and Syringes. Based on Diabetes, the market is segmented into Type I Diabetes and Type II Diabetes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Human Insulin Market

The expanding incidence of diabetes globally serves as a critical catalyst for the human insulin market. According to the International Diabetes Federation, approximately 463 million adults had diabetes in 2019, with predictions forecasting that this figure could soar to 700 million by 2045. This escalating diabetic population intensifies the need for insulin, thereby propelling market growth. Notably, nations such as China and India have experienced a notable rise in diabetes cases, attributed to shifts in lifestyle and dietary practices, which in turn has spurred an increased requirement for human insulin to manage these conditions effectively.

Restraints in the Human Insulin Market

The human insulin market faces several constraints primarily due to regulatory challenges and patent protections that limit competition and market entry. The process of acquiring regulatory approvals for new insulin products or biosimilars is demanding, necessitating thorough testing and adherence to strict guidelines, which can delay product availability. Furthermore, patent exclusivity on specific insulin formulations restricts the emergence of generic alternatives, thereby limiting choices for patients and hindering overall market expansion. For example, the exclusivity surrounding particular long-acting insulin analogs has effectively stifled the introduction of biosimilar options in the marketplace, exacerbating these constraints and impacting accessibility.

Market Trends of the Human Insulin Market

The Human Insulin market is currently experiencing a significant shift towards analog insulin formulations, driven by their superior benefits in diabetes management. Unlike traditional human insulin, which has limitations in terms of onset and duration, analog insulins provide rapid action and enhanced glycemic control, leading to improved patient outcomes. The rising adoption of long-acting analogs such as insulin glargine (Lantus) and insulin detemir (Levemir) has reshaped market dynamics, capturing substantial market share due to their favorable pharmacokinetic profiles. This trend underscores the growing preference among healthcare professionals and patients for precise insulin therapies, marking a transformative phase in diabetes treatment options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Human Insulin Market Size by Product & CAGR (2025-2032)

• Market Overview
• HI Drugs
• HI Delivery Devices

Global Human Insulin Market Size by Type & CAGR (2025-2032)

• Market Overview
• Insulin Analogs and Biosimilars
  • Rapid-acting
  • Long-acting
  • Premixed
• HI Biologics
  • Short-acting
  • Intermediate-acting
  • Premixed

Global Human Insulin Market Size by Brand & CAGR (2025-2032)

• Market Overview
• HI Analogs and Biosimilars
  • Lantus
  • NovoRapid/Novolog
  • Humalog
  • Other Brands
• HI Biologics
  • Actrapid, Insulatard, and Mixtard
  • Humulin
  • Insuman

Global Human Insulin Market Size by Delivery Devices & CAGR (2025-2032)

• Market Overview
• Pens
  • Reusable
  • Disposable
• Pen Needles
  • Standard
  • Safety
• Syringes

Global Human Insulin Market Size by Diabetes & CAGR (2025-2032)

• Market Overview
• Type I Diabetes
• Type II Diabetes

Global Human Insulin Market Size & CAGR (2025-2032)

• North America (Product, Type, Brand, Delivery Devices, Diabetes)
  • US
  • Canada
• Europe (Product, Type, Brand, Delivery Devices, Diabetes)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Type, Brand, Delivery Devices, Diabetes)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Type, Brand, Delivery Devices, Diabetes)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Type, Brand, Delivery Devices, Diabetes)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Julphar (United Arab Emirates)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oramed Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adocia (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gan & Lee Pharmaceuticals (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Senseonics Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations